Company Profile
Catalyst Pharmaceutical Stock Price, News & Analysis
- Ticker:
- CPRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
31.49 USD (+0.03%)
Close
Last updated: July 14, 2026
3.83B USD
Market cap
Why the stock is moving
Current closing-price context is not available for CPRX.
Company overview
Business overview
Catalyst Pharmaceuticals is a rare-neurology company focused on therapies for neuromuscular and orphan indications.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Catalyst sits in specialty biopharma.
Business Model Characteristics
The business combines commercial rare-disease revenue with a pipeline aimed at extending the franchise into additional orphan markets.
Position Within the Biotechnology Landscape
Catalyst is a steady orphan-drug name whose stock is driven more by commercial execution than by broad pipeline risk.
Future catalysts
Catalyst Pharmaceuticals's catalysts are Firdapse and AGAMREE execution, along with any rare-disease or label-expansion update that deepens the franchise. The business is still driven by commercial execution in orphan disease.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Catalyst Pharmaceutical (CPRX)?
Catalyst Pharmaceutical (CPRX) most recently closed at 31.49 USD, a +0.03% move versus the previous session.
What is the market cap of Catalyst Pharmaceutical (CPRX)?
Catalyst Pharmaceutical currently has a market capitalization of 3.83B USD on BioPharmSignal.
What does Catalyst Pharmaceutical do?
Catalyst Pharmaceuticals is a rare-neurology company focused on therapies for neuromuscular and orphan indications.
On which exchange is CPRX stock listed?
Catalyst Pharmaceutical (CPRX) is associated with NASDAQ, United States, Biopharma.
What is Catalyst?
Catalyst Pharmaceuticals's catalysts are Firdapse and AGAMREE execution, along with any rare-disease or label-expansion update that deepens the franchise.
Which conditions is Catalyst Pharmaceutical targeting with Catalyst?
Catalyst Pharmaceutical is associated with neurology based on its company overview and current catalyst commentary.
How does Catalyst Pharmaceutical describe recent progress with Catalyst?
Catalyst Pharmaceuticals's catalysts are Firdapse and AGAMREE execution, along with any rare-disease or label-expansion update that deepens the franchise.
What is Pharmaceuticals?
Catalyst Pharmaceuticals is a rare-neurology company focused on therapies for neuromuscular and orphan indications.